Fidelity Investments’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-13
Closed -$13 5717
2023
Q3
$13 Buy
+13
New +$9 ﹤0.01% 5154
2021
Q3
Hold
0
5207
2021
Q2
Hold
0
5060
2017
Q4
Sell
-2,168
Closed -$1.64M 2715
2017
Q3
$1.64M Sell
2,168
-658
-23% -$520K ﹤0.01% 2359
2017
Q2
$2.41M Sell
2,826
-105
-4% -$76.8K ﹤0.01% 2313
2017
Q1
$2.06M Sell
2,931
-265
-8% -$187K ﹤0.01% 2348
2016
Q4
$2.32M Buy
3,196
+57
+2% +$46.3K ﹤0.01% 2354
2016
Q3
$3.01M Buy
3,139
+62
+2% +$78.2K ﹤0.01% 2293
2016
Q2
$4.39M Sell
3,077
-85
-3% -$109K ﹤0.01% 2213
2016
Q1
$3.89M Sell
3,162
-97
-3% -$112K ﹤0.01% 2233
2015
Q4
$4.21M Buy
3,259
+330
+11% +$431K ﹤0.01% 2244
2015
Q3
$4.24M Buy
2,929
+385
+15% +$743K ﹤0.01% 2221
2015
Q2
$5.61M Sell
2,544
-49
-2% -$154K ﹤0.01% 2201
2015
Q1
$7.72M Buy
2,593
+74
+3% +$237K ﹤0.01% 2095
2014
Q4
$8.33M Buy
2,519
+31
+1% +$110K ﹤0.01% 2066
2014
Q3
$8.78M Buy
2,488
+64
+3% +$249K ﹤0.01% 2062
2014
Q2
$9.32M Sell
2,424
-175
-7% -$658K ﹤0.01% 2080
2014
Q1
$10.6M Sell
2,599
-13
-0.5% -$58K ﹤0.01% 1997
2013
Q4
$9.71M Buy
2,612
+274
+12% +$1.04M ﹤0.01% 1976
2013
Q3
$9.21M Buy
2,338
+954
+69% +$7.16M ﹤0.01% 1974
2013
Q2
$13.6M Buy
+1,384
New +$15.3M ﹤0.01% 1824

Other funds holding FRTX

Fidelity Investments's FRTX Position: Q4 2023 in Review

Fidelity Investments sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2023, closing a stake of 13 shares — an estimated $13 sold.

Fidelity Investments first reported a position in FRTX in Q2 2013 and held it in 19 quarters. The position peaked at $13.6M in Q2 2013. 1 fund tracked by Wall St. Rank holds FRTX as of Q4 2023.

  • Fidelity Investments reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Fidelity Investments sold 13 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $13.
  • Fidelity Investments first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 19 quarters.
  • Fidelity Investments's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $13.6M in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Fidelity Investments's 13F filing for Q4 2023, filed 13 Feb 2024.